Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

SUMO-1 modification activates the transcriptional response of p53.

Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DP, Hay RT.

EMBO J. 1999 Nov 15;18(22):6455-61.

2.

Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1.

Gostissa M, Hengstermann A, Fogal V, Sandy P, Schwarz SE, Scheffner M, Del Sal G.

EMBO J. 1999 Nov 15;18(22):6462-71.

3.

The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification.

Sampson DA, Wang M, Matunis MJ.

J Biol Chem. 2001 Jun 15;276(24):21664-9. Epub 2001 Mar 19.

4.

Involvement of PIAS1 in the sumoylation of tumor suppressor p53.

Kahyo T, Nishida T, Yasuda H.

Mol Cell. 2001 Sep;8(3):713-8.

5.

Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity.

Schmidt D, Müller S.

Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2872-7. Epub 2002 Feb 26.

6.

MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity.

Stindt MH, Carter S, Vigneron AM, Ryan KM, Vousden KH.

Cell Cycle. 2011 Sep 15;10(18):3176-88. Epub 2011 Sep 15.

7.

The Mdm-2 amino terminus is required for Mdm2 binding and SUMO-1 conjugation by the E2 SUMO-1 conjugating enzyme Ubc9.

Buschmann T, Lerner D, Lee CG, Ronai Z.

J Biol Chem. 2001 Nov 2;276(44):40389-95. Epub 2001 May 30.

8.

Functional analysis and intracellular localization of p53 modified by SUMO-1.

Kwek SS, Derry J, Tyner AL, Shen Z, Gudkov AV.

Oncogene. 2001 May 3;20(20):2587-99.

9.

Role of an N-terminal site of Ubc9 in SUMO-1, -2, and -3 binding and conjugation.

Tatham MH, Kim S, Yu B, Jaffray E, Song J, Zheng J, Rodriguez MS, Hay RT, Chen Y.

Biochemistry. 2003 Aug 26;42(33):9959-69.

PMID:
12924945
11.

Identification of a substrate recognition site on Ubc9.

Lin D, Tatham MH, Yu B, Kim S, Hay RT, Chen Y.

J Biol Chem. 2002 Jun 14;277(24):21740-8. Epub 2002 Mar 4.

12.

SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting.

Rodriguez MS, Dargemont C, Hay RT.

J Biol Chem. 2001 Apr 20;276(16):12654-9. Epub 2000 Dec 21.

13.

Ubch9 conjugates SUMO but not ubiquitin.

Desterro JM, Thomson J, Hay RT.

FEBS Lett. 1997 Nov 17;417(3):297-300.

14.
15.

P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2.

Xirodimas DP, Chisholm J, Desterro JM, Lane DP, Hay RT.

FEBS Lett. 2002 Sep 25;528(1-3):207-11.

16.

c-Jun and p53 activity is modulated by SUMO-1 modification.

Muller S, Berger M, Lehembre F, Seeler JS, Haupt Y, Dejean A.

J Biol Chem. 2000 May 5;275(18):13321-9.

17.

SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53.

Buschmann T, Fuchs SY, Lee CG, Pan ZQ, Ronai Z.

Cell. 2000 Jun 23;101(7):753-62. Erratum in: Cell 2001 Nov 16;107(4):549. Retraction in: Fuchs SY, Lee CG, Pan ZQ, Ronai Z. Cell. 2002 Aug 23;110(4):531.

18.
19.
20.

Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1).

Poukka H, Karvonen U, Janne OA, Palvimo JJ.

Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14145-50.

Supplemental Content

Support Center